Ondrusek N, Abramovitch R, Pencharz P, Koren G
Hospital for Sick Children, Toronto.
J Med Ethics. 1998 Jun;24(3):158-65. doi: 10.1136/jme.24.3.158.
This study examined the quality of children's assent to a clinical trial. In subjects younger than 9 years of age, understanding of most aspects of the study was found to be poor to non-existent. Understanding of procedures was poor in almost all subjects. In addition, voluntariness may have been compromised in many subjects by their belief that failure to complete the study would displease others. If the fact that a child's assent has been obtained is used to justify the exposure of that child to the potential harm of a non-therapeutic blood sample, the assent must be meaningful. In the nutrition study observed here, the quality of the assent of children younger than 9 years of age was very poor. The assent therefore did not provide a valid justification for requesting a blood sample from these children. This study indicates that most children younger than 9 years of age cannot be expected to consent or assent to clinical research in a meaningful way. The current age of 7 years for initiating assent (in addition to parental consent) is possibly not appropriate and should be reconsidered.
本研究考察了儿童对一项临床试验的同意质量。在9岁以下的受试者中,发现他们对该研究大多数方面的理解很差或完全没有理解。几乎所有受试者对研究程序的理解都很差。此外,许多受试者的自愿性可能因他们认为不完成研究会让他人不悦而受到影响。如果以获得儿童同意这一事实来为让该儿童暴露于非治疗性血样采集的潜在危害中进行辩护,那么这种同意必须是有意义的。在此观察的营养研究中,9岁以下儿童的同意质量非常差。因此,这种同意并不能为从这些儿童身上采集血样提供有效的正当理由。本研究表明,大多数9岁以下儿童不太可能以有意义的方式同意或赞同临床研究。目前设定的7岁开始获得同意(除了父母同意之外)的年龄可能并不合适,应该重新考虑。